Aldosterone bloCkade for Health ImproVementEvaluation in end-stage renal disease. proposal for a randomised double-blind placebo-controlled trial in the United Kingdom (ACHIEVE-UK)
People with kidney failure who need dialysis are at high risk of heart failure and heart-related death. There are currently no proven treatments to reduce this risk, as previous trials of heart failure treatments have tended to exclude people with kidney problems. Spironolactone is a drug that works by blocking the effects of a hormone (aldosterone), which can cause high blood pressure and damage the heart. It can be an effective treatment for people with heart failure, but more evidence is needed about whether it can be beneficial for people on dialysis. ACHIEVE is an international clinical trial aiming to find out if spironolactone reduces heart failure and heart-related deaths in people on dialysis for kidney failure. The trial will recruit 2750 people worldwide. The BHF is funding a team led by Professor Patrick Mark at the University of Glasgow to recruit 600 UK participants into the study. Half of the participants will be randomly assigned to receive spironolactone, and the other half will receive inactive tablets (placebo). If the trial finds that spironolactone is beneficial and safe, it could lead to this drug being routinely prescribed to people on dialysis for kidney failure. This has the potential to address an important unmet need and help reduce heart-related complications in people with chronic kidney disease.
Project details
| Grant amount | £674,797 |
|---|---|
| Grant type | Clinical Studies |
| Application type | Clinical Study |
| Start Date | 01 January 1900 |
| Duration | 4 years, 8 months |
| Reference | CS/20/2/34731 |
| Status | In Progress |
